199103-19-0

Basic information

• Product Name: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE
• Synonyms: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE;1-Piperidinecarboxylic acid, 4-[(Methylsulfonyl)oxy]-, phenylMethyl ester;benzyl 4-(methanesulfonyloxy)piperidine-1-carboxylate;Benzyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate;1-Cbz-4-(mesyloxy)piperidine
• CAS NO: 199103-19-0
• Molecular Formula: C₁₄H₁₉NO₅S
• Molecular Weight: 313.36936
• Mol File: 199103-19-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 492.3±44.0 °C(Predicted)
• Appearance: /
• Density: 1.31±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -3.07±0.40(Predicted)
• CAS DataBase Reference: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE(199103-19-0)
• EPA Substance Registry System: 1-((BENZYLOXY)CARBONYL)PIPERIDIN-4-YL METHANESULFONATE(199103-19-0)

Safety Data

• Hazardous Substances Data: 199103-19-0(Hazardous Substances Data)

Usage

Uses

Benzyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate is used as an intermediate for the preparation of conformationally restricted saturated nitrogen heterocyclic sulfonyl chloride.

Upstream product

• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 7143-01-3 Methanesulfonic anhydride 
• 501-53-1 benzyl chloroformate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 161609-84-3 4-cyanopiperidine-1-carboxylic acid benzyl ester 
• 287953-54-2 4-(chlorosulfonyl)piperidine-1-carboxylic acid benzyl ester 
• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 146827-60-3 4-(acetylthio)-1-(benzyloxycarbonyl)piperidine 

Relevant articles and documents

BENZAMIDES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. More particularly, provided are pharmaceutical composition of these compounds and methods of their preparation and use thereof.

NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS

The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES

Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a condition, disorder, or disease mediated by a lipid kinase or a protein kinase with benzimidazoles, for example, of Formula I or II, and pharmaceutical compositions thereof. Also provided herein are benzimidazoles, and pharmaceutical compositions thereof; and methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.